What is MOTS-c?

The short answer

MOTS-c is a small peptide made from a gene found in the tiny power plants of cells.

What it is
Mitochondria-encoded peptide acting as a metabolic (AMPK) signal.
What people look into
Weight, aging

8 sources
Status as of October 4, 2026
How we source
Ellum doesn't sell peptides.

By Ellum EditorialPublished October 6, 2026Updated October 11, 2026AI use

Get updates on MOTS-c

State

We'll store your email, your state, the page you're on and the peptides selected below (pre-selected from this page; untick any). Together these can reveal health interests. We use them only for what you tick below and to count sign-ups by state and peptide, without emails, to plan where the clinic opens and for reports that show only totals. Our hosting, database and email providers handle them for us. We pass them to a doctor or clinic only if you tick that box, and we don't sell them. Withdraw anytime with the unsubscribe link or at hello@ellumclinic.com. Consumer Health Data Privacy Policy

Ellum's sign-ups are for adults 18 and over.

Peptides: MOTS-c (1 selected) · edit

Peptides you're interested inMOTS-c

Add another molecule

What we may email you about

Notify me when an Ellum Clinic doctor can see me in my state

Send me updates on MOTS-c

More options (optional): research, doctor contact, paid offers

Contact me about taking part in research (optional)

Send my email, state and peptides to Ellum Clinic or a doctor licensed in my state, so they can contact me about care (optional)

Email me paid offers from clinics and health companies, picked for my peptides and state. Ellum sends them; the companies don't get my details (optional)

What it is

Type: Mitochondrial-derived peptide (16-aa)
Also known as: motc, mots c peptide, mitochondrial peptide
How it works: Mitochondria-encoded peptide acting as a metabolic (AMPK) signal.

Regulatory status

Not FDA-approved · advisory vote July 2026 · no FDA decision How we label status

As of October 4, 2026, MOTS-c is not FDA-approved. On July 23, 2026, FDA's compounding advisory committee voted to recommend adding it to the 503A bulks list; FDA staff had recommended against it. FDA has not proposed that change.

See MOTS-c in the Index →

Federal (FDA): Not FDA-approved
503A compounding: No category since 2026-04-22 (nomination withdrawn); PCAC recommended 2026-07-23/24; no proposed rule as of 2026-10-04 (as of October 4, 2026)
PCAC history: 2026-07-23: recommended 7-5-2 (free base and acetate; uses reviewed: obesity, osteoporosis; count as read into FDA's meeting recording; written minutes not posted as of 2026-10-04); FDA staff: against
WADA 2026: S4.4.1

Timeline

Scroll sideways to see all columns.

Date	What happened	Source
April 16, 2026	Federal Register notice of an FDA Pharmacy Compounding Advisory Committee meeting lists MOTS-c among bulk drug substances under consideration for the 503A bulks list.	Federal Register, event of April 16, 2026, on federalregister.gov
July 23, 2026	FDA presentations for the Pharmacy Compounding Advisory Committee meeting cover MOTS-c as a bulk drug substance under consideration for the 503A bulks list.	FDA, event of July 23, 2026, on fda.gov

References

Sources as of October 4, 2026